

# Gerald MÃ¼nch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4728869/publications.pdf>

Version: 2024-02-01

100  
papers

6,903  
citations

46918

47  
h-index

62479

80  
g-index

101  
all docs

101  
docs citations

101  
times ranked

8938  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ternstroenol F: a new pentacyclic triterpenoid saponin isolated from the Australian rainforest plant <i>Ternstroemia cherry</i> . <i>Natural Product Research</i> , 2023, 37, 2421-2426.	1.0	5
2	Acronyols A and B, new anti-inflammatory prenylated phloroglucinols from the fruits of <i>Acronychia crassipetala</i> . <i>Natural Product Research</i> , 2022, 36, 4358-4364.	1.0	2
3	Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2022, 129, 755-771.	1.4	9
4	Synergistic Anti-Inflammatory Activity of Ginger and Turmeric Extracts in Inhibiting Lipopolysaccharide and Interferon- $\beta$ -Induced Proinflammatory Mediators. <i>Molecules</i> , 2022, 27, 3877.	1.7	11
5	Potential anti-neuroinflammatory compounds from Australian plants – A review. <i>Neurochemistry International</i> , 2021, 142, 104897.	1.9	8
6	Identification of tetragocarbone C and sideroxylin as the most potent anti-inflammatory components of <i>Syncarpia glomulifera</i> . <i>Fytoterapia</i> , 2021, 150, 104843.	1.1	2
7	The effect of aging and chronic microglia activation on the morphology and numbers of the cerebellar Purkinje cells. <i>Neuroscience Letters</i> , 2021, 751, 135807.	1.0	9
8	Therapeutic Opportunities for Food Supplements in Neurodegenerative Disease and Depression. <i>Frontiers in Nutrition</i> , 2021, 8, 669846.	1.6	21
9	Spatial Memory and Microglia Activation in a Mouse Model of Chronic Neuroinflammation and the Anti-inflammatory Effects of Apigenin. <i>Frontiers in Neuroscience</i> , 2021, 15, 699329.	1.4	23
10	Synergistic Protective Effect of Curcumin and Resveratrol against Oxidative Stress in Endothelial EAhy926 Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-13.	0.5	14
11	Eupomatenes A – E: Neolignans isolated from the leaves of Australian rainforest plant <i>Eupomatia laurina</i> . <i>Fytoterapia</i> , 2021, 153, 104972.	1.1	3
12	In search of an anti-inflammatory drug for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2020, 16, 131-132.	4.9	35
13	Ternstroenols A – E: Undescribed pentacyclic triterpenoids from the Australian rainforest plant <i>Ternstroemia cherry</i> . <i>Phytochemistry</i> , 2020, 176, 112426.	1.4	6
14	The reciprocal EC50 value as a convenient measure of the potency of a compound in bioactivity-guided purification of natural products. <i>Fytoterapia</i> , 2020, 143, 104598.	1.1	18
15	Mulgravanols A and B, rare oxidized xanthenes and a new phloroglucinol isolated from the Australian rainforest plant <i>Waterhousea mulgraveana</i> (Myrtaceae). <i>Fytoterapia</i> , 2020, 143, 104595.	1.1	2
16	Evaluation of Phytosomal Curcumin as an Anti-inflammatory Agent for Chronic Glial Activation in the GFAP-IL6 Mouse Model. <i>Frontiers in Neuroscience</i> , 2020, 14, 170.	1.4	25
17	Effects of a solid lipid curcumin particle formulation on chronic activation of microglia and astroglia in the GFAP-IL6 mouse model. <i>Scientific Reports</i> , 2020, 10, 2365.	1.6	20
18	Costatamins A – C, new 4-phenylcoumarins with anti-inflammatory activity from the Australian woodland tree <i>Angophora costata</i> (Myrtaceae). <i>Fytoterapia</i> , 2019, 133, 171-174.	1.1	8

#	ARTICLE	IF	CITATIONS
19	A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 255.e1-255.e9.	0.7	24
20	The differential impact of acute microglia activation on the excitability of cholinergic neurons in the mouse medial septum. <i>Brain Structure and Function</i> , 2019, 224, 2297-2309.	1.2	11
21	Chronic Microglial Activation in the GFAP-IL6 Mouse Contributes to Age-Dependent Cerebellar Volume Loss and Impairment in Motor Function. <i>Frontiers in Neuroscience</i> , 2019, 13, 303.	1.4	42
22	Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines. <i>CNS Drugs</i> , 2019, 33, 457-480.	2.7	27
23	Determination of glyoxal and methylglyoxal in serum by UHPLC coupled with fluorescence detection. <i>Analytical Biochemistry</i> , 2019, 573, 51-66.	1.1	19
24	Influence of the fat/carbohydrate component of snack food on energy intake pattern and reinforcing properties in rodents. <i>Behavioural Brain Research</i> , 2019, 364, 328-333.	1.2	7
25	Assessment of diets containing curcumin, epigallocatechin-3-gallate, docosahexaenoic acid and $\alpha$ -lipoic acid on amyloid load and inflammation in a male transgenic mouse model of Alzheimer's disease: Are combinations more effective?. <i>Neurobiology of Disease</i> , 2019, 124, 505-519.	2.1	36
26	Hydrogen peroxide mediates pro-inflammatory cell-to-cell signaling: a new therapeutic target for inflammation?. <i>Neural Regeneration Research</i> , 2019, 14, 1430.	1.6	25
27	Investigation Into the Effects of Tenilsetam on Markers of Neuroinflammation in GFAP-IL6 Mice. <i>Pharmaceutical Research</i> , 2018, 35, 22.	1.7	11
28	Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. <i>European Journal of Nutrition</i> , 2018, 57, 929-938.	1.8	142
29	A New Anti-inflammatory Phenolic Monosaccharide from the Australian Native Rainforest Plant <i>Elaeocarpus Eumundi</i> . <i>Natural Product Communications</i> , 2018, 13, 1934578X1801300.	0.2	1
30	Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4224-4231.	1.8	32
31	Anti-inflammatory activity of prenyl and geranyloxy furanocoumarins from <i>Citrus garrawayi</i> (Rutaceae). <i>Phytochemistry Letters</i> , 2018, 27, 197-202.	0.6	12
32	High bioavailability curcumin: an anti-inflammatory and neurosupportive bioactive nutrient for neurodegenerative diseases characterized by chronic neuroinflammation. <i>Archives of Toxicology</i> , 2017, 91, 1623-1634.	1.9	94
33	Activation of Macrophages and Microglia by Interferon- $\beta$ and Lipopolysaccharide Increases Methylglyoxal Production: A New Mechanism in the Development of Vascular Complications and Cognitive Decline in Type 2 Diabetes Mellitus?. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 467-479.	1.2	17
34	Molecular Anti-inflammatory Mechanisms of Retinoids and Carotenoids in Alzheimer's Disease: a Review of Current Evidence. <i>Journal of Molecular Neuroscience</i> , 2017, 61, 289-304.	1.1	83
35	The Effects of a Normal Rate versus a Slow Intervalled Rate of Oral Nutrient Intake and Intravenous Low Rate Macronutrient Application on Psychophysical Function – Two Pilot Studies. <i>Frontiers in Psychology</i> , 2017, 8, 1031.	1.1	1
36	The Effects of Different Isocaloric Oral Nutrient Solutions on Psychophysical, Metabolic, Cognitive, and Olfactory Function in Young Male Subjects. <i>Frontiers in Psychology</i> , 2017, 8, 1988.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Anti-Inflammatory Chemical Profiling of the Australian Rainforest Tree <i>Alphitonia petriei</i> (Rhamnaceae). <i>Molecules</i> , 2016, 21, 1521.	1.7	23
38	Medicinal Plants of the Australian Aboriginal Dharawal People Exhibiting Anti-Inflammatory Activity. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-8.	0.5	24
39	Evidence For and Against a Pathogenic Role of Reduced $\beta$ -Secretase Activity in Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 781-799.	1.2	44
40	Revelation of molecular basis for chromium toxicity by phenotypes of <i>Saccharomyces cerevisiae</i> gene deletion mutants. <i>Metallomics</i> , 2016, 8, 542-550.	1.0	27
41	Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 31450.	1.6	186
42	Molecular insight into arsenic toxicity via the genome-wide deletion mutant screening of <i>Saccharomyces cerevisiae</i> . <i>Metallomics</i> , 2016, 8, 228-235.	1.0	21
43	Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds. <i>Pharmacological Research</i> , 2016, 103, 80-94.	3.1	78
44	S-allyl-L-cysteine and isoliquiritigenin improve mitochondrial function in cellular models of oxidative and nitrosative stress. <i>Food Chemistry</i> , 2016, 194, 843-848.	4.2	24
45	Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease. <i>Neurochemistry International</i> , 2016, 95, 63-74.	1.9	145
46	Neuroprotection of Neuro2a cells and the cytokine suppressive and anti-inflammatory mode of action of resveratrol in activated RAW264.7 macrophages and C8B4 microglia. <i>Neurochemistry International</i> , 2016, 95, 46-54.	1.9	44
47	Plant polyphenols as inhibitors of NF- $\kappa$ B induced cytokine production - a potential anti-inflammatory treatment for Alzheimer's disease?. <i>Frontiers in Molecular Neuroscience</i> , 2015, 8, 24.	1.4	115
48	Anti-inflammatory activity of cinnamon ( <i>C. zeylanicum</i> and <i>C. cassia</i> ) extracts - identification of E-cinnamaldehyde and o-methoxy cinnamaldehyde as the most potent bioactive compounds. <i>Food and Function</i> , 2015, 6, 910-919.	2.1	93
49	Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer's disease brain. <i>Neurobiology of Aging</i> , 2015, 36, 753-761.	1.5	65
50	An in vitro study of anti-inflammatory activity of standardised <i>Andrographis paniculata</i> extracts and pure andrographolide. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 18.	3.7	41
51	Type 2 Diabetes, Skin Autofluorescence, and Brain Atrophy. <i>Diabetes</i> , 2015, 64, 279-283.	0.3	71
52	Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease. <i>Neural Regeneration Research</i> , 2015, 10, 1181.	1.6	151
53	Chronic Neuroinflammation in Alzheimer's Disease: New Perspectives on Animal Models and Promising Candidate Drugs. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	88
54	Determination of anti-inflammatory activities of standardised preparations of plant- and mushroom-based foods. <i>European Journal of Nutrition</i> , 2014, 53, 335-343.	1.8	31

#	ARTICLE	IF	CITATIONS
55	Bacopamonnieri (L.) exerts anti-inflammatory effects on cells of the innate immune system in vitro. Food and Function, 2014, 5, 517-520.	2.1	18
56	Natural Compounds and Plant Extracts as Therapeutics Against Chronic Inflammation in Alzheimer's Disease – A Translational Perspective. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1175-1191.	0.8	58
57	Proenergetic effects of resveratrol in the murine neuronal cell line Neuro2a. Molecular Nutrition and Food Research, 2013, 57, 1901-1907.	1.5	8
58	Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells. Redox Biology, 2013, 1, 441-445.	3.9	113
59	Chronic Inflammation Alters Production and Release of Glutathione and Related Thiols in Human U373 Astroglial Cells. Cellular and Molecular Neurobiology, 2013, 33, 19-30.	1.7	45
60	Methylglyoxal, Cognitive Function and Cerebral Atrophy in Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 68-73.	1.7	78
61	Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids, 2012, 42, 1221-1236.	1.2	105
62	Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiology of Aging, 2011, 32, 763-777.	1.5	413
63	Activated astroglia during chronic inflammation in Alzheimer's disease – Do they neglect their neurosupportive roles?. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010, 690, 40-49.	0.4	139
64	Advanced glycation end products as biomarkers and gerontotoxins – A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?. Experimental Gerontology, 2010, 45, 744-751.	1.2	89
65	A Versatile High Throughput Screening System for the Simultaneous Identification of Anti-Inflammatory and Neuroprotective Compounds. Journal of Alzheimer's Disease, 2010, 19, 451-464.	1.2	26
66	Activated astrocytes: a therapeutic target in Alzheimer's disease?. Expert Review of Neurotherapeutics, 2009, 9, 1585-1594.	1.4	73
67	Plant-derived polyphenols attenuate lipopolysaccharide-induced nitric oxide and tumour necrosis factor production in murine microglia and macrophages. Molecular Nutrition and Food Research, 2008, 52, 427-438.	1.5	64
68	Inflammation and the Redox-sensitive AGE-RAGE Pathway as a Therapeutic Target in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2008, 1126, 147-151.	1.8	57
69	Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Advanced Drug Delivery Reviews, 2008, 60, 1463-1470.	6.6	288
70	Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array. Cytokine, 2008, 41, 198-203.	1.4	49
71	Effect of Pseudophosphorylation and Cross-linking by Lipid Peroxidation and Advanced Glycation End Product Precursors on Tau Aggregation and Filament Formation. Journal of Biological Chemistry, 2007, 282, 6984-6991.	1.6	100
72	Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains. Neurobiology of Aging, 2007, 28, 29-41.	1.5	101

#	ARTICLE	IF	CITATIONS
73	Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. , 2007, 113, 154-164.		248
74	Carbonyl stress and NMDA receptor activation contribute to methylglyoxal neurotoxicity. Free Radical Biology and Medicine, 2006, 40, 779-790.	1.3	53
75	Methylglyoxal, Glyoxal, and Their Detoxification in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2005, 1043, 211-216.	1.8	132
76	Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. Journal of Neurochemistry, 2005, 92, 255-263.	2.1	199
77	The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal. Neurotoxicity Research, 2005, 7, 95-101.	1.3	69
78	Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts" Neurobiology of Aging, 2005, 26, 465-474.	1.5	35
79	Age- and Stage-dependent Accumulation of Advanced Glycation End Products in Intracellular Deposits in Normal and Alzheimer's Disease Brains. Cerebral Cortex, 2004, 15, 211-220.	1.6	152
80	Advanced glycation endproducts and pro-inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology. Journal of Neurochemistry, 2004, 86, 283-289.	2.1	39
81	Microglial activation induces cell death, inhibits neurite outgrowth and causes neurite retraction of differentiated neuroblastoma cells. Experimental Brain Research, 2003, 150, 1-8.	0.7	72
82	Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs). Journal of Neurochemistry, 2003, 87, 44-55.	2.1	93
83	"Amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon-" and "advanced glycation endproducts" in a murine microglia cell line. European Journal of Neuroscience, 2003, 17, 813-821.	1.2	88
84	Advanced Glycation Endproducts Induce Changes in Glucose Consumption, Lactate Production, and ATP Levels in SH-SY5Y Neuroblastoma Cells by a Redox-Sensitive Mechanism. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 1307-1313.	2.4	27
85	Advanced glycation endproducts cause lipid peroxidation in the human neuronal cell line SH-SY5Y. Journal of Alzheimer's Disease, 2003, 5, 25-30.	1.2	41
86	Amyloid "peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. Journal of Alzheimer's Disease, 2002, 4, 193-201.	1.2	155
87	Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Research, 2002, 953, 135-143.	1.1	215
88	Advanced glycation endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism. Neuroscience Letters, 2001, 312, 29-32.	1.0	40
89	Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Archives of Gerontology and Geriatrics, 2001, 32, 275-282.	1.4	158
90	Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. European Journal of Neuroscience, 2001, 14, 1961-1967.	1.2	100

#	ARTICLE	IF	CITATIONS
91	AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?. Biogerontology, 2001, 2, 19-34.	2.0	110
92	Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimerâ€™s disease. Brain Research, 2001, 920, 32-40.	1.1	151
93	Transition metal-mediated glycooxidation accelerates cross-linking of Î²-amyloid peptide. FEBS Journal, 2000, 267, 4171-4178.	0.2	101
94	Amino acid specificity of glycation and proteinâ€™AGE crosslinking reactivities determined with a dipeptide SPOT library. Nature Biotechnology, 1999, 17, 1006-1010.	9.4	108
95	Investigations on oxidative stress and therapeutical implications in dementia. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S68-S73.	1.8	71
96	Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of Î²-amyloid peptide. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1997, 1360, 17-29.	1.8	160
97	Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Research Reviews, 1997, 23, 134-143.	9.1	257
98	Identification of a Gs-protein coupling domain to the Î²-adrenoceptor using site-specific synthetic peptides. FEBS Letters, 1990, 261, 294-298.	1.3	57
99	Mapping of Î²-adrenoceptor coupling domains to Gs -protein by site-specific synthetic peptides. FEBS Letters, 1989, 254, 89-93.	1.3	67
100	Identification of Nrf2 activators from the roots of Valeriana officinalis. Planta Medica, 0, , .	0.7	0